HCM
SLDB icon

Highline Capital Management’s Solid Biosciences SLDB Stock Holding History

Highline Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,667
Closed -$2.6M – 40
2018
Q3 		$2.6M Buy
3,667
+173
+5% +$109K 0.12% 32
2018
Q2 		$1.87M Buy
+3,494
New +$1.08M 0.06% 41

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highline Capital Management's SLDB Position: Q4 2018 in Review

Highline Capital Management sold out of Solid Biosciences (SLDB) in Q4 2018, closing a stake of 3,667 shares — an estimated $2.6M sold.

Highline Capital Management first reported a position in SLDB in Q2 2018 and held it in 2 quarters. The position peaked at $2.6M in Q3 2018. 75 funds tracked by Wall St. Rank hold SLDB as of Q4 2018.

  • Highline Capital Management reported no remaining Solid Biosciences position as of Q4 2018 after selling out during the quarter.
  • Highline Capital Management sold 3,667 Solid Biosciences shares in Q4 2018, an estimated $2.6M.
  • Highline Capital Management first reported a position in Solid Biosciences in Q2 2018 and held it in 2 quarters.
  • Highline Capital Management's Solid Biosciences position peaked at $2.6M in Q3 2018.
  • 75 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2018.

Based on Highline Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.